CD44 and prostate carcinoma: Accordingly the expression of candidate prostate cancer stem cell markers such as CD49f [11] and CD44 [28](not shown) was not found to be elevated in TROP2high LNCaP cells in vitro or in post-treatment recurring LNCaP xenografts in vivo.